NASDAQ:IART - Integra lifesciences Stock Price, Price Target & More

$57.17 +0.21 (+0.37 %)

(As of 04/19/2018 10:12 AM ET)

Previous Close$56.96

Today's Range$56.79 - $57.40

52-Week Range$41.51 - $58.17

Volume16,223 shs

Average Volume497,740 shs

Market Capitalization$4.43 billion

P/E Ratio29.09

Dividend YieldN/A

Beta0.65

About Integra lifesciences (NASDAQ:IART)

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies. It offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment. The company also sells approximately 60,000 instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, it provides regenerative technology products for the treatment of acute and chronic wounds; and surgical tissue repair products for hernia repair, peripheral nerve repair and protection, and tendon repair. Further, the company sells hardware products, such as bone and joint fixation, and joint replacement devices; implants; and instruments, which provide for the orthopedic reconstruction of bone in the hand, wrist, elbow, and shoulder, as well as the foot, ankle, and leg below the knee in the extremity bone and joint reconstruction procedures. Integra LifeSciences Holdings Corporation offers its products directly through various sales forces and other distribution channels in the United States, Europe, and internationally. The company was founded in 1989 and is headquartered in Plainsboro, New Jersey.

Receive IART News and Ratings via Email

Sign-up to receive the latest news and ratings for IART and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Analytical instruments

Sub-IndustryHealth Care Equipment

SectorMedical

SymbolNASDAQ:IART

CUSIP45798520

Webwww.integralife.com

Phone609-275-0500

Debt

Debt-to-Equity Ratio1.85%

Current Ratio2.36%

Quick Ratio1.51%

Price-To-Earnings

Trailing P/E Ratio29.09

Forward P/E Ratio24.54

P/E Growth1.73

Sales & Book Value

Annual Sales$1.19 billion

Price / Sales3.80

Cash Flow$3.1796 per share

Price / Cash17.98

Book Value$12.26 per share

Price / Book4.66

Profitability

EPS (Most Recent Fiscal Year)$1.94

Net Income$64.74 million

Net Margins5.45%

Return on Equity16.94%

Return on Assets6.27%

Miscellaneous

Employees4,400

Outstanding Shares78,960,000

How to Become a New Pot Stock Millionaire

Integra lifesciences (NASDAQ:IART) Frequently Asked Questions

What is Integra lifesciences' stock symbol?

Integra lifesciences trades on the NASDAQ under the ticker symbol "IART."

When did Integra lifesciences' stock split? How did Integra lifesciences' stock split work?

Integra lifesciences's stock split on Tuesday, January 3rd 2017. The 2-1 split was announced on Thursday, December 22nd 2016. The newly issued shares were issued to shareholders after the closing bell on Wednesday, December 21st 2016. An investor that had 100 shares of Integra lifesciences stock prior to the split would have 200 shares after the split.

How were Integra lifesciences' earnings last quarter?

Integra lifesciences (NASDAQ:IART) issued its quarterly earnings data on Tuesday, February, 27th. The life sciences company reported $0.64 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.56 by $0.08. The life sciences company earned $368.60 million during the quarter, compared to the consensus estimate of $362.64 million. Integra lifesciences had a net margin of 5.45% and a return on equity of 16.94%. The firm's revenue was up 44.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.52 EPS. View Integra lifesciences' Earnings History.

When is Integra lifesciences' next earnings date?

Integra lifesciences is scheduled to release their next quarterly earnings announcement on Wednesday, April, 25th 2018. View Earnings Estimates for Integra lifesciences.

What guidance has Integra lifesciences issued on next quarter's earnings?

Integra lifesciences updated its FY18 earnings guidance on Tuesday, February, 27th. The company provided earnings per share (EPS) guidance of $2.25-2.35 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.30. The company issued revenue guidance of $1.46-1.48 billion, compared to the consensus revenue estimate of $1.47 billion.

What price target have analysts set for IART?

12 brokerages have issued 1-year price objectives for Integra lifesciences' shares. Their predictions range from $50.00 to $63.00. On average, they expect Integra lifesciences' stock price to reach $55.90 in the next twelve months. View Analyst Ratings for Integra lifesciences.

What are Wall Street analysts saying about Integra lifesciences stock?

Here are some recent quotes from research analysts about Integra lifesciences stock:

1. Cantor Fitzgerald analysts commented, "IART announced preliminary 4Q revenue of $365MM, beating FactSet consensus by $13MM. The beat was driven by better than expected contribution from the Codman and DermaScience acquisitions." (1/5/2018)
2. According to Zacks Investment Research, "Integra LifeSciences' contracting adjusted operating margin and adjusted gross margin have been causing troubles for the company of late. Also the company’s decision to sell its certain neurosurgery assets to Natus Medical may hamper its business in near term. However, the strong year-over-year increase in revenues on the back of strong growth within Orthopedics and Tissue Technologies segment buoys optimism. Raised full-year revenue guidance is indicative of this bullish trend to remain. We are happy with the fact that, the company is efficiently executing its growth plan through an efficient management team. However, the slashed full-year adjusted earnings range remains a concern. Overall, over the past year, Integra Lifesciences has been trading above the broader industry." (12/26/2017)

Who are some of Integra lifesciences' key competitors?

Some companies that are related to Integra lifesciences include PerkinElmer (PKI), Bio-Rad Laboratories (BIO), Bruker (BRKR), Coherent (COHR), Horiba (HRIBF), Accelerate Diagnostics (AXDX), Quanterix (QTRX), Pacific Biosciences (PACB), Fluidigm (FLDM), Harvard Bioscience (HBIO), HTG Molecular Diagnostics (HTGM), pSivida (EYPT) and Precipio (PRPO).

Who are Integra lifesciences' key executives?

Integra lifesciences' management team includes the folowing people:

Mr. Peter J. Arduini, Pres, CEO & Director (Age 53)
Dr. Richard E. Caruso Ph.D., Founder and Chairman Emeritus (Age 75)
Mr. Glenn G. Coleman, Corp. VP & CFO (Age 50)
Mr. Richard D. Gorelick, Corp. VP of Admin., Gen. Counsel and Sec. (Age 57)
Mr. Daniel L. Reuvers, Corp. VP and Pres of Specialty Surgical Solutions (Age 55)

Has Integra lifesciences been receiving favorable news coverage?

News coverage about IART stock has been trending somewhat positive on Thursday, Accern Sentiment reports. Accern identifies negative and positive press coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Integra lifesciences earned a media sentiment score of 0.06 on Accern's scale. They also assigned media stories about the life sciences company an impact score of 45.89 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near term.

How do I buy shares of Integra lifesciences?

Shares of IART can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Integra lifesciences' stock price today?

One share of IART stock can currently be purchased for approximately $57.17.

How big of a company is Integra lifesciences?

Integra lifesciences has a market capitalization of $4.43 billion and generates $1.19 billion in revenue each year. The life sciences company earns $64.74 million in net income (profit) each year or $1.94 on an earnings per share basis. Integra lifesciences employs 4,400 workers across the globe.

How can I contact Integra lifesciences?

Integra lifesciences' mailing address is 311 ENTERPRISE DRIVE, PLAINSBORO NJ, 08536. The life sciences company can be reached via phone at 609-275-0500 or via email at [email protected]

MarketBeat Community Rating for Integra lifesciences (IART)

Community Ranking:		2.4 out of 5 ( )
Outperform Votes:		299 (Vote Outperform)
Underperform Votes:		314 (Vote Underperform)
Total Votes:		613

MarketBeat's community ratings are surveys of what our community members think about Integra lifesciences and other stocks. Vote "Outperform" if you believe IART will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IART will underperform the S&P 500 over the long term. You may vote once every thirty days.

Integra lifesciences (NASDAQ:IART) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

12 Wall Street analysts have issued ratings and price targets for Integra lifesciences in the last 12 months. Their average twelve-month price target is $55.90, suggesting that the stock has a possible downside of 2.22%. The high price target for IART is $63.00 and the low price target for IART is $50.00. There are currently 9 hold ratings and 3 buy ratings for the stock, resulting in a consensus rating of "Hold."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Hold	Hold	Hold	Buy
Consensus Rating Score:	2.25	2.33	2.27	2.80
Ratings Breakdown:	0 Sell Rating(s) 9 Hold Rating(s) 3 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 8 Hold Rating(s) 4 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 8 Hold Rating(s) 3 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 2 Hold Rating(s) 8 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$55.90	$54.10	$52.4444	$54.20
Price Target Upside:	2.22% downside	4.60% upside	6.66% upside	9.30% upside

Integra lifesciences (NASDAQ:IART) Consensus Price Target History

Price Target History for Integra lifesciences (NASDAQ:IART)

Integra lifesciences (NASDAQ:IART) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
4/11/2018	JPMorgan Chase	Boost Price Target	Neutral -> Neutral	$50.00 -> $55.00	Low
4/5/2018	BTIG Research	Initiated Coverage	Neutral	$56.00	Low
3/29/2018	Oppenheimer	Set Price Target	Buy	$58.00	N/A
3/1/2018	Jefferies Group	Reiterated Rating	Buy	$63.00	Low
2/28/2018	JMP Securities	Boost Price Target	Market Outperform -> Market Outperform	$57.00 -> $60.00	Medium
1/9/2018	Barclays	Reiterated Rating	Hold	$53.00	Low
1/5/2018	Cantor Fitzgerald	Reiterated Rating	Neutral -> Neutral	$52.00	Medium
1/2/2018	UBS	Downgrade	Market Perform		Low
1/2/2018	Raymond James	Reiterated Rating	Outperform -> Market Perform	$55.00	Medium
1/2/2018	Bank of America	Downgrade	Buy -> Neutral		High
11/9/2017	Royal Bank of Canada	Reiterated Rating	Sector Perform -> Sector Perform	$48.00 -> $50.00	N/A
10/29/2017	Wells Fargo	Downgrade	Outperform -> Market Perform		N/A
3/22/2017	Piper Jaffray	Reiterated Rating	Overweight	$47.00	Low
10/28/2016	Lake Street Capital	Upgrade	Hold -> Buy	$46.00	N/A
9/23/2016	Argus	Boost Price Target	Buy	$45.00 -> $52.50	N/A

(Data available from 4/19/2016 forward)

Integra lifesciences (NASDAQ:IART) Earnings History and Estimates Chart

Earnings by Quarter for Integra lifesciences (NASDAQ:IART)

Integra lifesciences (NASDAQ:IART) Earnings Estimates

2018 EPS Consensus Estimate: $2.32
2019 EPS Consensus Estimate: $2.67

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	4	$0.45	$0.51	$0.49
Q2 2018	4	$0.55	$0.58	$0.56
Q3 2018	4	$0.57	$0.60	$0.58
Q4 2018	4	$0.63	$0.74	$0.69
Q1 2019	2	$0.56	$0.59	$0.58
Q2 2019	2	$0.63	$0.68	$0.66
Q3 2019	2	$0.67	$0.69	$0.68
Q4 2019	2	$0.75	$0.77	$0.76

Integra lifesciences (NASDAQ IART) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
4/25/2018		$0.49					N/A
2/27/2018	Q4 2017	$0.56	$0.64	$362.64 million	$368.60 million	View	N/A
10/26/2017	Q3 2017	$0.47	$0.45	$286.00 million	$278.83 million	View	N/A
7/26/2017	Q2 2017	$0.45	$0.45	$283.58 million	$282.16 million	View	N/A
4/26/2017	Q1 17	$0.40	$0.39	$254.19 million	$258.60 million	View	N/A
2/23/2017	Q4 2016	$0.52	$0.52	$257.27 million	$255.70 million	View	N/A
10/27/2016	Q3	$0.89	$0.93	$249.30 million	$250.30 million	View	Listen
7/28/2016	Q216	$0.76	$0.79	$243.17 million	$249.30 million	View	Listen
4/27/2016	Q116	$0.73	$0.74	$230.66 million	$236.80 million	View	Listen
2/25/2016	Q4	$0.86	$0.87	$241.11 million	$241.20 million	View	Listen
11/3/2015	Q315	$0.74	$0.75	$224.08 million	$226.40 million	View	Listen
7/30/2015	Q215	$0.73	$0.79	$239.91 million	$244.10 million	View	Listen
4/30/2015	Q115	$0.63	$0.76	$229.69 million	$233.70 million	View	N/A
2/24/2015	Q414	$0.89	$0.94	$244.39 million	$252.20 million	View	Listen
11/3/2014	Q314	$0.74	$0.76	$233.50 million	$229.70 million	View	Listen
8/5/2014	Q214	$0.63	$0.68	$229.32 million	$231.40 million	View	N/A
5/1/2014	Q114	$0.58	$0.57	$213.30 million	$215.00 million	View	N/A
2/25/2014	Q413	$0.81	$0.78	$223.37 million	$220.80 million	View	N/A
10/28/2013	Q313	$0.70	$0.72	$214.05 million	$213.20 million	View	N/A
8/1/2013	Q2 2013	$0.55	$0.60	$207.30 million	$205.50 million	View	N/A
5/2/2013	Q1 2013	$0.37	$0.39	$195.20 million	$196.70 million	View	N/A
2/21/2013	Q4 2012	$0.76	$0.78	$215.90 million	$214.40 million	View	N/A
10/24/2012		$0.77	$0.85			View	N/A
7/26/2012		$0.69	$0.74			View	N/A
4/25/2012		$0.60	$0.71			View	N/A
2/23/2012		$0.55	$0.72			View	N/A
10/31/2011		$0.77	$0.77			View	N/A
7/28/2011		$0.61	$0.70			View	N/A
4/28/2011		$0.66	$0.66			View	N/A
2/24/2011		$0.73	$0.80			View	N/A
10/28/2010	Q3 2010	$0.33	$0.33			View	N/A
7/29/2010	Q2 2010	$0.32	$0.34			View	N/A
5/3/2010	Q1 2010	$0.28	$0.31			View	N/A
3/1/2010	Q4 2009	$0.29	$0.30			View	N/A
11/4/2009	Q3 2009	$0.26	$0.27			View	N/A
8/6/2009	Q2 2009	$0.25	$0.26			View	N/A
5/6/2009	Q1 2009	$0.23	$0.23			View	N/A
3/2/2009	Q4 2008	$0.28	$0.27			View	N/A
11/7/2008	Q3 2008	$0.23	$0.24			View	N/A
8/11/2008	Q2 2008	$0.23	$0.25			View	N/A
6/4/2008	Q1 2008	$0.20	$0.25			View	N/A
5/17/2008	Q4 2007		$0.27			View	N/A

(Earnings results data provided by Zacks Investment Research)

Integra lifesciences (NASDAQ:IART) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

Integra lifesciences (NASDAQ IART) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 5.10%
Institutional Ownership Percentage: 90.39%

Insider Trading History for Integra lifesciences (NASDAQ:IART)

Institutional Ownership by Quarter for Integra lifesciences (NASDAQ:IART)

Integra lifesciences (NASDAQ IART) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/14/2018	Glenn Coleman	VP	Sell	8,769	$56.10	$491,940.90
3/9/2018	Joseph Vinhais	VP	Sell	6,800	$54.13	$368,084.00
3/8/2018	Richard E Caruso	Major Shareholder	Sell	32,880	$53.68	$1,764,998.40
3/5/2018	Christian S Schade	Director	Sell	15,658	$52.88	$827,995.04	75,262
2/26/2018	Keith Bradley	Director	Sell	15,658	$55.00	$861,190.00	37,074
11/20/2017	Jeffrey Mosebrook	Insider	Sell	160	$47.41	$7,585.60
11/14/2017	Richard D Gorelick	VP	Sell	1,500	$47.19	$70,785.00	21,665
10/31/2017	Barbara B Hill	Director	Buy	10,768	$46.66	$502,434.88	55,540
8/4/2017	Donald E Morel Jr	Director	Buy	10,000	$49.25	$492,500.00	29,612
8/3/2017	Donald E Morel Jr	Director	Buy	2,500	$49.29	$123,225.00	29,612
8/1/2017	Barbara B Hill	Director	Buy	5,050	$49.33	$249,116.50	44,772
5/25/2017	Stuart Essig	Director	Sell	135,000	$49.90	$6,736,500.00	2,077,475
5/23/2017	Stuart Essig	Director	Sell	140,000	$48.01	$6,721,400.00
5/4/2017	Glenn Coleman	VP	Sell	13,865	$45.91	$636,542.15	18,519
5/4/2017	James M Sullivan	Director	Sell	15,658	$45.89	$718,545.62	70,154
11/8/2016	Peter J Arduini	CEO	Sell	24,009	$79.51	$1,908,955.59	25,593
8/23/2016	Raymond G Murphy	Director	Sell	2,600	$86.64	$225,264.00	33,047
8/9/2016	Peter J Arduini	CEO	Sell	24,009	$84.52	$2,029,240.68	29,602
8/4/2016	Raymond G Murphy	Director	Sell	2,610	$84.83	$221,406.30	33,057
8/1/2016	Richard D Gorelick	VP	Sell	4,000	$84.60	$338,400.00	9,702
5/9/2016	Joseph Vinhais	VP	Sell	972	$73.36	$71,305.92	4,311
5/4/2016	Glenn Coleman	CFO	Sell	3,563	$70.62	$251,619.06	12,263
5/3/2016	Christian S Schade	Director	Sell	7,829	$70.42	$551,318.18	18,550
5/2/2016	Daniel L Reuvers	VP	Sell	1,000	$71.43	$71,430.00	9,747
4/29/2016	Richard D Gorelick	VP	Sell	4,000	$70.72	$282,880.00	13,702
4/27/2016	Stuart Essig	Director	Sell	104,390	$70.15	$7,322,958.50	1,064,709
4/6/2016	Stuart Essig	Director	Sell	21,100	$66.19	$1,396,609.00	981,419
4/5/2016	Stuart Essig	Director	Sell	83,290	$66.68	$5,553,777.20	1,002,469
4/4/2016	Stuart Essig	Director	Sell	42,150	$67.26	$2,835,009.00	1,002,469
5/7/2015	Stuart Essig	Director	Sell	75,000	$64.32	$4,824,000.00
5/6/2015	Stuart Essig	Director	Sell	125,000	$64.83	$8,103,750.00
1/2/2015	Judith Ogrady	VP	Sell	3,500	$53.33	$186,655.00
10/28/2014	Stuart Essig	Director	Sell	147,098	$49.58	$7,293,118.84
10/27/2014	Stuart Essig	Director	Sell	41,268	$49.56	$2,045,242.08
9/2/2014	Judith Ogrady	VP	Sell	2,500	$49.82	$124,550.00
8/27/2014	Richard D Gorelick	VP	Sell	7,000	$50.03	$350,210.00
8/25/2014	John B Henneman III	CAO	Sell	20,000	$50.12	$1,002,400.00
8/22/2014	Deborah A Leonetti	VP	Sell	1,000	$50.96	$50,960.00
8/8/2014	Brian Larkin	VP	Sell	1,947	$48.28	$94,001.16
7/30/2014	Stuart Essig	Director	Sell	50,800	$47.76	$2,426,208.00
7/23/2014	Stuart Essig	Director	Sell	27,819	$47.80	$1,329,748.20
7/1/2014	Judith Ogrady	VP	Sell	2,500	$47.54	$118,850.00
6/23/2014	Stuart Essig	Director	Sell	21,381	$47.76	$1,021,156.56
4/3/2014	Stuart Essig	Director	Sell	6,344	$46.01	$291,887.44	1,051,166
4/2/2014	Stuart Essig	Director	Sell	76,177	$46.05	$3,507,950.85	1,057,510
3/31/2014	Stuart Essig	Director	Sell	17,479	$46.05	$804,907.95	1,133,687
3/10/2014	Deborah Leonetti	VP	Sell	7,563	$49.22	$372,250.86	9,955
3/4/2014	Richard Gorelick	VP	Sell	2,000	$47.98	$95,960.00	18,296
2/28/2014	Christian Schade	Director	Sell	7,500	$47.06	$352,950.00	11,902
2/27/2014	Brian Larkin	VP	Sell	3,265	$46.15	$150,679.75	10,256
2/27/2014	John Henneman III	CFO	Sell	5,000	$46.07	$230,350.00	63,611
1/16/2014	Stuart Essig	Director	Sell	8,037	$49.59	$398,554.83	1,151,166
1/14/2014	Stuart Essig	Director	Sell	10,600	$49.50	$524,700.00	1,151,166
1/13/2014	Stuart Essig	Director	Sell	99,032	$49.51	$4,903,074.32	1,151,166
1/9/2014	Stuart Essig	Director	Sell	114,431	$49.58	$5,673,488.98	1,151,166
8/30/2013	Richard Gorelick	VP	Sell	3,000	$40.79	$122,370.00	20,296
8/23/2013	Deborah Leonetti	VP	Sell	8,906	$41.68	$371,202.08	17,518
8/19/2013	Brian Larkin	VP	Sell	7,490	$41.90	$313,831.00	13,521
8/19/2013	John Henneman III	CFO	Sell	30,000	$42.08	$1,262,400.00	72,669
8/1/2013	Judith Ogrady	VP	Sell	1,000	$39.50	$39,500.00
7/30/2013	Judith Ogrady	VP	Sell	2,000	$38.50	$77,000.00
5/31/2013	Jerry E Corbin	VP	Sell	1,876	$38.07	$71,419.32

(Data available from 1/1/2013 forward)

Integra lifesciences (NASDAQ IART) News Headlines

Source:

Date	Headline
	Integra lifesciences (IART) Given Average Rating of "Hold" by Analysts www.americanbankingnews.com - April 18 at 1:35 PM
	Integra lifesciences (IART) to Release Earnings on Wednesday www.americanbankingnews.com - April 18 at 4:20 AM
	Zacks: Analysts Anticipate Integra lifesciences (IART) Will Post Quarterly Sales of $349.61 Million www.americanbankingnews.com - April 17 at 5:01 AM
	Integra lifesciences (IART) Lowered to "Hold" at BidaskClub www.americanbankingnews.com - April 16 at 6:30 PM
	Integra lifesciences (IART) Rating Reiterated by Oppenheimer www.americanbankingnews.com - April 15 at 8:22 PM
	Integra lifesciences (IART) Given a $65.00 Price Target by Cantor Fitzgerald Analysts www.americanbankingnews.com - April 15 at 5:39 PM
	Integra lifesciences (IART) Raised to "Hold" at Zacks Investment Research www.americanbankingnews.com - April 15 at 2:53 PM
	Integra lifesciences (IART) Given New $55.00 Price Target at Raymond James Financial www.americanbankingnews.com - April 15 at 12:00 PM
	Analysts Anticipate Integra lifesciences (IART) Will Announce Earnings of $0.49 Per Share www.americanbankingnews.com - April 15 at 1:17 AM
	IART Crosses Above Average Analyst Target www.nasdaq.com - April 13 at 5:15 PM
	Integra LifeSciences to Host First Quarter 2018 Earnings Results Conference ... globenewswire.com - April 12 at 9:12 AM
	Integra LifeSciences to Host First Quarter 2018 Earnings Results Conference Call on April 25, 2018 finance.yahoo.com - April 11 at 5:11 PM
	Integra lifesciences (IART) Price Target Raised to $55.00 at JPMorgan Chase www.americanbankingnews.com - April 11 at 9:23 AM
	Integra lifesciences (IART) Now Covered by Analysts at BTIG Research www.americanbankingnews.com - April 5 at 11:32 AM
	Integra lifesciences (IART) Rating Reiterated by UBS www.americanbankingnews.com - April 2 at 6:59 PM
	Integra lifesciences (IART) Receives "Sector Perform" Rating from Royal Bank of Canada www.americanbankingnews.com - March 31 at 6:06 PM
	Integra lifesciences (IART) Downgraded to Market Perform at UBS www.americanbankingnews.com - March 31 at 12:16 PM
	Integra lifesciences (IART) Downgraded by Bank of America www.americanbankingnews.com - March 31 at 11:54 AM
	$349.61 Million in Sales Expected for Integra lifesciences (IART) This Quarter www.americanbankingnews.com - March 31 at 4:36 AM
	Integra lifesciences (IART) PT Set at $58.00 by Oppenheimer www.americanbankingnews.com - March 30 at 1:49 PM
	Why Is Integra LifeSciences (IART) Up 3.6% Since Its Last Earnings Report? finance.yahoo.com - March 29 at 5:13 PM
	Integra lifesciences (IART) Earns Buy Rating from Oppenheimer www.americanbankingnews.com - March 28 at 9:16 PM
	Integra Lifesciences (IART) Upgraded by BidaskClub to "Sell" www.americanbankingnews.com - March 25 at 2:34 PM
	Integra Lifesciences Holdings Corp (IART) Given Average Rating of "Hold" by Brokerages www.americanbankingnews.com - March 24 at 1:53 PM
	Integra Lifesciences (IART) Raised to Buy at BidaskClub www.americanbankingnews.com - March 23 at 7:56 PM
	Pre-Market Technical Scan on Medical Supplies Equities -- Insulet, Integra LifeSciences, Mazor Robotics, and Microbot Medical www.bizjournals.com - March 23 at 8:42 AM
	Oppenheimer Reaffirms Buy Rating for Integra Lifesciences (IART) www.americanbankingnews.com - March 22 at 4:08 PM
	Why Does Dentsply Sirona Expect Its Earnings Margins to Be under Pressure in 2018? finance.yahoo.com - March 21 at 5:22 PM
	Integra Lifesciences (IART) Upgraded to "Hold" by BidaskClub www.americanbankingnews.com - March 17 at 5:36 PM
	Integra Lifesciences Holdings Corp (IART) VP Sells $491,940.90 in Stock www.americanbankingnews.com - March 15 at 7:46 PM
	Reading Dentsply Sirona’s Recent Stock Performance finance.yahoo.com - March 15 at 5:48 PM
	$349.68 Million in Sales Expected for Integra Lifesciences Holdings Corp (IART) This Quarter www.americanbankingnews.com - March 14 at 5:15 PM
	Integra Lifesciences Holdings Corp (IART) VP Sells $368,084.00 in Stock www.americanbankingnews.com - March 12 at 7:38 PM
	Integra Lifesciences Holdings Corp (IART) Major Shareholder Richard E. Caruso Sells 32,880 Shares www.americanbankingnews.com - March 12 at 7:21 PM
	Integra Lifesciences Holdings Corp (IART) Expected to Announce Earnings of $0.49 Per Share www.americanbankingnews.com - March 12 at 1:24 AM
	Contrasting Integra Lifesciences (IART) and CONMED (CNMD) www.americanbankingnews.com - March 9 at 11:08 PM
	Integra Lifesciences Holdings Corp (IART) Director Sells $827,995.04 in Stock www.americanbankingnews.com - March 6 at 6:32 PM
	Integra LifeSciences Holdings (IART) Presents At Raymond James 39th Annual Institutional Investors Conference - Slideshow seekingalpha.com - March 6 at 5:26 PM
	Integra LifeSciences Banks on CSS Segment, Competition Rife www.zacks.com - March 6 at 8:36 AM
	Sectoral Asset Management Inc Has $5.90 Million Stake in Integra Lifesciences Holdings Corp (IART) www.americanbankingnews.com - March 5 at 3:34 PM
	OppenheimerFunds Inc. Trims Position in Integra Lifesciences Holdings Corp (IART) www.americanbankingnews.com - March 5 at 10:06 AM
	Integra Lifesciences Holdings Corp (IART) Stake Increased by Rhumbline Advisers www.americanbankingnews.com - March 5 at 9:40 AM
	Cantor Fitzgerald Research Analysts Lower Earnings Estimates for Integra Lifesciences Holdings Corp (IART) www.americanbankingnews.com - March 5 at 5:38 AM
	Integra Lifesciences Holdings Corp (IART) Holdings Increased by BlackRock Inc. www.americanbankingnews.com - March 5 at 5:08 AM
	Integra Lifesciences (IART) Earns Buy Rating from Jefferies Group www.americanbankingnews.com - March 4 at 12:58 PM
	Teacher Retirement System of Texas Raises Holdings in Integra Lifesciences Holdings Corp (IART) www.americanbankingnews.com - March 4 at 7:06 AM
	Wells Fargo & Company MN Purchases 63,204 Shares of Integra Lifesciences Holdings Corp (IART) www.americanbankingnews.com - March 2 at 7:38 PM
	Brokers Offer Predictions for Integra Lifesciences Holdings Corp's FY2018 Earnings (IART) www.americanbankingnews.com - March 2 at 12:50 PM
	FY2018 Earnings Estimate for Integra Lifesciences Holdings Corp (IART) Issued By Northcoast Research www.americanbankingnews.com - March 2 at 12:50 PM
	Eaton Vance Management Has $6.32 Million Stake in Integra Lifesciences Holdings Corp (IART) www.americanbankingnews.com - March 2 at 12:12 PM

Integra lifesciences (NASDAQ:IART) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Integra lifesciences (NASDAQ:IART) Income Statement, Balance Sheet and Cash Flow Statement

Integra lifesciences (NASDAQ IART) Stock Chart for Thursday, April, 19, 2018

Loading chart…

This page was last updated on 4/19/2018 by MarketBeat.com Staff